Catalog No.
Product Name
Application
Product Information
Citations
-
NMPRTase Inhibitor
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.- T Nakajo, .et al. , Biochem Biophys Res Commun, 2024, Oct 30:731:150371 PMID: 39004065
- Takeshi Katayoshi, .et al. , Sci Rep, 2022, Nov 9;12(1):19040 PMID: 36352014
- Takeshi Nakamura, .et al. , Shimane Journal of Medical Science, 2022, 38 (2), 59-66
- Takeshi Katayoshi, .et al. , J Photochem Photobiol B, 2021, Jun 12;221:112238 PMID: 34130091
- Yool Lee, .et al. , Sci Adv, 2021, 7
- Peter M LoCoco, .et al. , eLife, 2017, 6: e29626 PMID: 29125463
-
Thymidine phosphorylase activator
Doxifluridine is a thymidine phosphorylase activator for PC9-DPE2 cells with IC50 of 0.62 μM.- Takashi Azuma, .et al. , SEP PURIF TECHNOL, 2019, Apr; 212: 483-489
- Azuma T, .et al. , Environ Sci Pollut Res Int, 2017, Aug;24(23):19021-19030 PMID: 28660504
- Azuma T, .et al. , Sci Total Environ, 2016, Apr 1;548-549:189-197 PMID: 26802347
-
Thymidine phosphorylase inhibitor
Tipiralacil hydrochloride, also known as TPI, is a thymidine phosphorylase inhibitor (TPI).
-
Glycogen Phosphorylase Inhibitor
Glycogen phosphorylase-IN-1 is a potent inhibitor of human liver glycogen phosphorylase (hlGPa), demonstrating IC50 values of 53 nM for the enzyme and 380 nM for glucose production from hepatocyte glycogen. This compound is particularly relevant for research applications targeting type 2 diabetes, as it effectively reduces glycogen-derived glucose production in hepatocytes, thereby influencing glucose homeostasis. -
Glycogen Phosphorylase Inhibitor
BAY R3401 is an orally active inhibitor of glycogen phosphorylase, demonstrating irreversible and non-selective inhibition of hepatic glycogenolysis. This compound effectively inhibits glycogenolysis in liver cells, exhibiting IC50 values of 27.06 μM in HL-7702 cells and 52.83 μM in HepG2 cells. BAY R3401 serves as a valuable tool for research focused on type 2 diabetes and its associated metabolic pathways. -
Glycogen Phosphorylase Inhibitor
GPi688 is a potent and orally active inhibitor of glycogen phosphorylase (GPa), demonstrating IC50 values of 19 nM, 61 nM, and 12 nM for human liver GPa, rat liver GPa, and human skeletal muscle GPa, respectively. This compound effectively inhibits glucagon-mediated glucose output in rat primary hepatocytes. GPi688 is a valuable tool for investigating glucagon-mediated hyperglycemia and related metabolic disorders in research applications. -
Phosphorylase Inhibitor
Deoxyadenosine diphosphate sodium is a nucleoside diphosphate that functions as a phosphorylase inhibitor. It plays a crucial role in DNA synthesis and repair processes by inhibiting polynucleotide phosphorylase, thereby interfering with the polymerization of ADP and CDP. This compound is valuable for research applications focused on understanding DNA metabolism and enzymatic regulation in cellular systems. -
UPP1 Inhibitor
TK-112690 is a selective inhibitor of uridine phosphorylase 1 (UPP1). It demonstrates inhibitory effects on murine small intestinal uridine phosphorylase with an IC50 of 12.5 μM and on human small intestinal UPP1 with an IC50 of 20.0 μM in vitro. By increasing plasma uridine concentration in mice, TK-112690 can be utilized to explore therapeutic avenues in cancer research and pulmonary fibrosis studies.

